Abstract
Out of the 15 discrete proteins encoding the total amount of genetic information in the chromosomes of human immunodeficiency virus type 1; three perform the vital enzymatic functions i.e. a reverse transcription, an integration, and proteolysis. The HIV integrase is the new validated drug target against AIDS amongst all essential enzymes due to the lack of the human homologue. In last few years quite, a few but potent inhibitors inhibiting HIV-1 integrase have been recognized and hence have gained a state-of-the-art for treating the infection caused by HIV-1. The greater understanding of HIV-integrase biological structure has further lead to continuous efforts for the proposal of novel inhibitors targeting diverse steps in the progression of integration with the primary goal to overcome resistance due to the rapid occurrence of integrase mutations in the treated patients. This review is focused on various aspects of the recently approved HIVintegrase inhibitor “dolutegravir”, its efficacy, safety profiles with the clinical data and molecular modeling studies highlighting its importance over the already approved HIV-integrase inhibitors.
Keywords: AIDS, HIV, integrase, dolutegravir, reteroviral, homologue.
Current HIV Research
Title:A Novel Integrase Targeting Agent to Explore the Future Prospective of HIV Eradication: Dolutegravir
Volume: 12 Issue: 5
Author(s): Bawneet K. Narang, Gurpreet K. Grewal, Subhajit Roy, Jitender Bariwal, Manish K. Gupta and Ravindra K. Rawal
Affiliation:
Keywords: AIDS, HIV, integrase, dolutegravir, reteroviral, homologue.
Abstract: Out of the 15 discrete proteins encoding the total amount of genetic information in the chromosomes of human immunodeficiency virus type 1; three perform the vital enzymatic functions i.e. a reverse transcription, an integration, and proteolysis. The HIV integrase is the new validated drug target against AIDS amongst all essential enzymes due to the lack of the human homologue. In last few years quite, a few but potent inhibitors inhibiting HIV-1 integrase have been recognized and hence have gained a state-of-the-art for treating the infection caused by HIV-1. The greater understanding of HIV-integrase biological structure has further lead to continuous efforts for the proposal of novel inhibitors targeting diverse steps in the progression of integration with the primary goal to overcome resistance due to the rapid occurrence of integrase mutations in the treated patients. This review is focused on various aspects of the recently approved HIVintegrase inhibitor “dolutegravir”, its efficacy, safety profiles with the clinical data and molecular modeling studies highlighting its importance over the already approved HIV-integrase inhibitors.
Export Options
About this article
Cite this article as:
Narang K. Bawneet, Grewal K. Gurpreet, Roy Subhajit, Bariwal Jitender, Gupta K. Manish and Rawal K. Ravindra, A Novel Integrase Targeting Agent to Explore the Future Prospective of HIV Eradication: Dolutegravir, Current HIV Research 2014; 12 (5) . https://dx.doi.org/10.2174/1570162X12666140807150753
DOI https://dx.doi.org/10.2174/1570162X12666140807150753 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Drug Metabolism Letters Strategies for Antimicrobial Drug Delivery to Biofilm
Current Pharmaceutical Design Yeast Genomics and Drug Target Identification
Combinatorial Chemistry & High Throughput Screening Association of Common Variants in the IL-33/ST2 Axis with Ischemic Stroke
Current Neurovascular Research Glucocorticoids in Patients with Rheumatic Diseases: Friends or Enemies of Bone?
Current Medicinal Chemistry COPD: Optimal Current Treatment Strategies and Promising New Therapeutic Modalities
Current Respiratory Medicine Reviews Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Combined Therapy for Gastrointestinal Carcinomas: Exploiting Synergies Between Gene Therapy and Classical Chemo-Radiotherapy
Current Gene Therapy Foreword: The Year in Review: Comments on Plants, Cyclodextrins, Microbiota, and Diabetes
Current Pharmaceutical Design Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Glutamate and Multiple Sclerosis
Current Medicinal Chemistry Synthesis of Novel Imine Stilbene Analogs Exhibiting Potent Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Proposed Benchmark Methods for Analyzing Acai (Euterpe oleraceae Mart.)
The Natural Products Journal The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets The DDX3 Subfamily of the DEAD Box Helicases: Divergent Roles as Unveiled by Studying Different Organisms and In Vitro Assays
Current Medicinal Chemistry Opioid Peptides and Innate Immune Response in Mollusc
Protein & Peptide Letters Peaceful Existence of Tumor Cells with Their Non-malignant Neighbors: The Trade of Tumor Cells with Tumor Microenvironment
Current Chemical Biology Castration-resistant Prostate Cancer: The Targeting of Bone Microenvironment-related Survival Factors For Prostate Cancer Cells
Clinical Cancer Drugs Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine